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Background. Virologic failure (VF) on a first-line ritonavir-boosted protease inhibitor (PI/r) regimen is associ-
ated with low rates of resistance, but optimal management after failure is unknown.
Methods. The analysis included participants in randomized trials who experienced VF on a first-line regimen
of PI/r plus 2 nucleoside reverse transcriptase inhibitors (NRTIs) and had at least 24 weeks of follow-up after
VF. Antiretroviral management and virologic suppression (human immunodeficiency virus type 1 [HIV-1] RNA
<400 copies/mL) after VF were assessed.
Results. Of 209 participants, only 1 participant had major PI-associated treatment-emergent mutations at first-
line VF. The most common treatment approach after VF (66%) was to continue the same regimen. The virologic
suppression rate 24 weeks after VF was 64% for these participants, compared with 72% for those who changed reg-
imens (P = .19). Participants remaining on the same regimen had lower NRTI resistance rates (11% vs 30%; P = .003)
and higher CD4+ cell counts (median, 275 vs 213 cells/µL; P = .005) at VF than those who changed. Among partic-
ipants remaining on their first-line regimen, factors at or before VF significantly associated with subsequent virologic
suppression were achieving HIV-1 RNA <400 copies/mL before VF (odds ratio [OR], 3.39 [95% confidence interval
{CI}, 1.32–8.73]) and lower HIV-1 RNA at VF (OR for <10 000 vs ≥10 000 copies/mL, 3.35 [95% CI, 1.40–8.01]).
Better adherence after VF was also associated with subsequent suppression (OR for <100% vs 100%, 0.38 [95% CI,
.15–.97]). For participants who changed regimens, achieving HIV-1 RNA <400 copies/mL before VF also predicted
subsequent suppression.
Conclusions. For participants failing first-line PI/r with no or limited drug resistance, remaining on the same
regimen is a reasonable approach. Improving adherence is important to subsequent treatment success.
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Antiretroviral therapy (ART) that includes a ritonavir-
boosted protease inhibitor (PI/r) plus 2 nucleoside
reverse transcriptase inhibitors (NRTIs) is among
the first-line therapies recommended for human
immunodeficiency virus (HIV) infection in current
treatment guidelines [1, 2]. Although the effectiveness
of PI/r-based regimens as initial therapy is well estab-
lished, about 10%–20% of patients experience virologic
failure (VF) within 2 years [3–6].
A distinctive characteristic of PI/r regimens is that
those who experience VF rarely have detectable PI resis-
tance [7–10]. As a result, clinicians theoretically have
the option of continuing the same regimen or modify-
ing the treatment by changing to a different PI/r or in-
troducing a new drug class, such as a nonnucleoside
reverse transcriptase inhibitor (NNRTI). It is important
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to understand the outcome of different management strategies
after failure of PI/r-based first-line therapy, but few data exist, as
many first-line studies terminate follow-up soon after a partic-
ipant reaches the primary VF endpoint. Furthermore, the num-
ber of participants experiencing failure in any one study is
small.
This analysis evaluated therapeutic approaches and outcomes
among participants in 3 large randomized clinical trials under-
taken by the AIDS Clinical Trials Group (ACTG) who experi-
enced VF on first-line PI/r-based ART.
METHODS
Study Population
The study included all 3 randomized trials of initial ART
conducted by the ACTG that included a PI/r regimen and
was completed by June 2013. The study population included
participants who experienced VF on first-line PI/r plus 2
NRTIs while participating in ACTG A5142 [3], A5202 [4], or
A5208 trial 2 [5]; A5208 trial 1 [11] was not included, as partic-
ipants in that study had to have prior single-dose nevirapine ex-
posure. The design and main results of these studies have been
previously published [3–5]. The ACTG A5142 and A5202 trials
enrolled men and women in the United States. A5208 trial 2
enrolled women in eastern and southern Africa without prior
single-dose nevirapine exposure. These studies included
randomization to lopinavir/ritonavir (LPV/r) (A5142 and
A5208) or atazanavir/ritonavir (ATV/r) (A5202) as first-line
PI/r, with 1 of the following combinations of 2 NRTIs: lamivu-
dine plus either tenofovir, zidovudine, or stavudine in A5142;
tenofovir plus emtricitabine or lamivudine plus abacavir in
A5202; and tenofovir plus emtricitabine in A5208.
Participants who changed to a regimen other than PI/r plus 2
NRTIs prior to first-line VF and those who had <24 weeks of
follow-up after failure were excluded from the analysis.
First-line Virologic Failure and ART Management
HIV type 1 (HIV-1) RNA was measured in plasma using the
Ultrasensitive Roche Amplicor Monitor V1.5 in A5142 and
A5202, and the standard Roche Amplicor Monitor V1.5 in
A5208. First-line VF was defined similarly with little variation
among the 3 studies (Table 1).
Decisions regarding ART management after first-line VF
were made by site clinicians and participants. Real-time drug
resistance testing at VF was available in A5142 and A5202,
but was done retrospectively using stored samples at the end
of A5208; pretreatment drug resistance testing using stored
samples was performed retrospectively for participants experi-
encing VF in all 3 studies. Major resistance mutations were
defined mainly based on International Antiviral Society
(IAS)–USA [12, 13], and the details are shown in Table 1
along with the protocol-suggested management on first-line
virologic failure and study-provided ART.
Table 1. Definition of First-line Virologic Failure, Protocol-Suggested Postvirologic Failure Management, and Available Antiretroviral
Therapy and Major Resistance Mutation by ACTG Study
Definition A5142 A5202 A5208
Definition of first-line
virologic failure
HIV-1 RNA <1 log10 copies/mL below
baseline at/after 8 wk of ART or
≥200 copies/mL at/after 32 wk
confirmation of VF was required in a
subsequent plasma sample
HIV-1 RNA ≥1000 copies/mL at/after
16 wk or ≥200 copies/mL at/after
24 wk; confirmation of VF was
required in a subsequent plasma
sample
HIV-1 RNA <1 log10 copies/mL
below baseline at/after 12 wk or
≥400 copies/mL at/after 24 wk;
confirmation of VF was required in





Suggested second-line regimen is
EFV + additional agents selected by
genotypic resistance result
Alternatively, any regimen may be
chosen based on the genotypic
resistance test results
Subjects may remain on their study
regimen in consultation with their
primary care provider. If the CD4
count or the HIV-1 RNA returns to
the baseline level, subjects will be
strongly advised to change therapy
according to resistance test result
Suggested second-line regimen is
NVP-containing regimen, but
switching to a second-line
regimen is not mandatory.
Participants may remain on the
step 1 regimen at the discretion of
the participant and site
investigator
Study-provided ART EFV, LPV/r, d4T, TDF ABC/3TC, FTC/TDF, 3TC/ZDV, LPV/r,
ABC, ATV, ddI, EFV, FTC, FPV,
3TC, d4T, RTV, TDF, ZDV




IAS-USA (2006 version) [12] IAS-USA (2008 version) [13], as well
as T69D, L74I, and G190C/E/Q/T/V
for reverse transcriptase, and L24I,
F53L, I54V/A/T/S, G73C/S/T/A, and
N88D for protease
IAS-USA (2008 version) [13]
Abbreviations: 3TC, lamivudine; ABC, abacavir; ACTG, AIDS Clinical Trials Group; ART, antiretroviral therapy; ATV, atazanavir; d4T, stavudine; ddI, didanosine; EFV,
efavirenz; FPV, fosamprenavir; FTC, emtricitabine; HIV-1, human immunodeficiency virus type 1; IAS, International AIDS Society; LPV/r, lopinavir/ritonavir; NVP,
nevirapine; RTV, ritonavir; TDF, tenofovir; ZDV, zidovudine.
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Statistical Methods
The primary endpoint of the analysis was virologic suppression,
defined as HIV-1 RNA <400 copies/mL, at 24 weeks after con-
firmation of first-line VF. Missing values were considered as
lack of suppression unless the last HIV-1 RNA before 24
weeks was <400 copies/mL. For participants who changed
ART within 24 weeks after first-line VF confirmation, virologic
suppression at 24 weeks after regimen change was also
examined.
The following variables were evaluated for their association
with ART management following VF and with subsequent viro-
logic suppression: first-line ART regimen, HIV-1 RNA, and
CD4 cell count at ART initiation and at VF, HIV-1 RNA
<400 copies/mL at any time prior to VF, weeks from ART ini-
tiation to VF, change in CD4 count from ART initiation to VF,
age and drug resistance at VF, and last available self-reported
adherence (in the prior 4 days) within 24 weeks prior to
VF. Sex and race were only examined among A5142 and
A5202 participants because A5208 only included African
women, and all were black. The association between resistance
and ART management was also only examined among A5142
and A5202 participants, as real-time resistance results were
not available in A5208 to guide ART management. Partici-
pants who switched to a nonstandard second-line regimen
after VF (including a nonboosted PI or both an NNRTI and a
PI/r) were included in analyses of ART management after VF
but were excluded from analyses examining subsequent
suppression.
All analyses were stratified by ACTG study. To compare char-
acteristics and virologic suppression rates between participants
Figure 1. Consolidated Standards of Reporting Trials (CONSORT) diagram for inclusion and exclusion criteria. 1Among the 21 patients with some follow-
up, 16 stayed on their first-line ritonavir-boosted protease inhibitor (PI/r)–based regimen; 13 of the 21 (62%) had HIV-1 RNA <400 copies/mL at their last
available measurement after initial virologic failure. 2The 5 participants who changed to a nonstandard regimen included 3 who changed to an unboosted
protease inhibitor–containing regimen and 2 who changed to a PI/r + nonnucleoside reverse transcriptase regimen. Abbreviations: ART, antiretroviral therapy;
HIV-1, human immunodeficiency virus type 1; NRTI, nucleoside reverse transcriptase inhibitor; PI/r, ritonavir-boosted protease inhibitor.
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remaining on the same regimen vs changing regimen, and
among different regimens for those who changed regimens,
van Elteran and Cochran-Mantel-Haenszel tests were used for
continuous and categorical variables, respectively. To evaluate
factors associated with subsequent virologic suppression, multi-
variable logistic regression was constructed by stepwise variable
selection with P < .05 required for entry and subsequent reten-
tion. The following sensitivity analyses were conducted:
excluding participants whose HIV-1 RNA at VF was <400 cop-
ies/mL for both initial and confirmatory measurements; exclud-
ing participants from resource-limited settings (A5208); and
defining virologic suppression as HIV-1 RNA <200 copies/
mL instead of <400 copies/mL (limited to A5142 and A5202 be-
cause A5208 used the assay with lower limit of quantification of
400 copies/mL). All analyses were performed using SAS soft-
ware, version 9.2.










Characteristics prior to starting ART
Sex Female 24 (36%) 31 (29%) 35 (100%) 90 (43%)
Age, y Median (quartiles) 38 (32–42) 37 (31–44) 31 (26–38) 37 (30–42)
CD4 count, cells/µL Median (quartiles) 141 (46–248) 107 (32–302) 137 (80–178) 118 (42–253)
HIV-1 RNA, log10 copies/mL Median (quartiles) 4.8 (4.4–5.2) 4.8 (4.5–5.4) 5.4 (4.8–5.8) 4.8 (4.5–5.5)
First-line ART LPV/r + 3TC + TDF 20 (30%) 0 (0%) 0 (0%) 20 (10%)
LPV/r + 3TC + ZDV 28 (42%) 0 (0%) 0 (0%) 28 (13%)
LPV/r + 3TC +D4T 19 (28%) 0 (0%) 0 (0%) 19 (9%)
LPV/r + TDF + FTC 0 (0%) 0 (0%) 35 (100%) 35 (17%)
ATV/r + 3TC +ABC 0 (0%) 64 (60%) 0 (0%) 64 (31%)
ATV/r + TDF + FTC 0 (0%) 43 (40%) 0 (0%) 43 (21%)
Characteristics at first-line virologic failure
Age, y Median (quartiles) 39 (34–43) 39 (33–46) 33 (28–39) 38 (32–44)
Achieved HIV-1 RNA <400 copies/mL at
any time prior to initial failure
Yes 53 (79%) 85 (79%) 26 (74%) 164 (78%)
Weeks from ART initiation Median (quartiles) 39 (14–76) 37 (24–84) 48 (13–72) 39 (18–76)
HIV-1 RNA, log10 copies/mL Median (quartiles) 3.8 (3.2–4.7) 3.8 (3.0–4.6) 4.2 (3.3–5.0) 3.9 (3.2–4.7)
CD4 count, cells/µL Median (quartiles) 251 (187–370) 269 (156–425) 180 (129–316) 246 (160–404)
CD4 count change from ART initiation,
cells/µL
Median (quartiles) 95 (50–243) 100 (39–182) 74 (6–201) 96 (35–190)
Self-reported adherence within 4 d Prior
to clinic visit
Not on ART 6 (9%) 12 (11%) 1 (3%) 19 (9%)
<100% 23 (34%) 18 (17%) 7 (20%) 48 (23%)
100% 33 (49%) 70 (65%) 27 (77%) 130 (62%)
Unknown 5 (13%) 7 (2%) 0 12 (6%)
Drug resistancea Major PI-associatedb 0 (0%) 5 (5%) 0 (0%) 5 (3%)
Minor PI-associated 43 (88%) 96 (90%) 32 (100%) 171 (91%)
NNRTI-associatedc 1 (2%) 3 (3%) 3 (9%) 7 (4%)
NRTI- associatedd 12 (24%) 20 (19%) 6 (19%) 38 (20%)
Not available 18 0 3 21
Data are presented as No. (%) unless otherwise specified.
Abbreviations: 3TC, lamivudine; ABC, abacavir; ART, antiretroviral therapy; ATV/r, ritonavir-boosted atazanavir; d4T, stavudine; FTC, emtricitabine; HIV-1, human
immunodeficiency virus type 1; LPV/r, ritonavir-boosted lopinavir; NNRTI, nonnucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse-transcriptase
inhibitor; PI, protease inhibitor; TDF, tenofovir; ZDV, zidovudine.
a Resistance mutations were defined as those listed by the International Antiviral Society (IAS)–USA for A5142 (2006 version) [12] and A5208 (2008 version) [13]; for
A5202, they were defined as those listed by the IAS-USA 2008 version [13], as well as T69D, L74I, and G190C/E/Q/T/V for major reverse transcriptase–associated
mutations, and L24I, F53L, I54V/A/T/S, G73C/S/T/A, and N88D for major protease-associated mutations.
b Only 1 of the 5 participants selected a major protease-associated resistance mutation (N88S) after treatment initiation; the other 4 participants hadmutations (I54V,
L90M, L33F, and G73A/L90M, respectively) prior to starting treatment.
c All 7 participants had NNRTI-associated resistance mutations before treatment initiation.
d Fifteen participants selected NRTI-associated resistance mutations after treatment initiation; the other 23 participants had mutations present prior to starting
treatment. Among the 38 participants with NRTI-associated resistance mutations, 2 (5%) had K65R mutation, 20 (53%) had M184V mutation, and 3 (8%) had
thymidine-associated mutations.
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RESULTS
Characteristics at Pretreatment and at First-line Virologic Failure
Among the 1429 participants randomized to receive a first-line
PI/r-based regimen, 277 (19%) experienced study-defined VF.
Seven were not eligible for this analysis because they switched
to a regimen other than PI/r + 2 NRTIs prior to VF. Sixty-one
were excluded from the analysis because they were not followed
(n = 40) or had <24 weeks of follow-up (n = 21) after VF, either
because of study closure or because of loss to follow-up (Figure 1).
Among the 209 participants included, 67 (32%) were from
A5142 and 107 (51%) were from A5202 (thus 83% enrolled
in the United States), and 35 (17%) were from A5208 (enrolled
in Africa). Overall, 43% of participants were female, the median
pretreatment HIV-1 RNAwas 4.8 log10 copies/mL, and median
CD4 count was 118 cells/µL; 49% received LPV/r and 51% re-
ceived ATV/r as the PI/r component of first-line ART (Table 2).
Median time from ART initiation to confirmation of VF was
39 weeks, and 78% of participants achieved HIV-1 RNA <400
copies/mL at some time prior to VF. At VF, the median HIV-1
RNA was 3.9 log10 copies/mL, the median CD4 count was 246
cells/µL, and the median CD4 count increase from pretreatment
was 96 cells/µL. Self-reported ART adherence within the 4 days
prior to VF was 100% for 62% of participants and <100% for
23% (9% reported not being on ART, and 6% had no report).
Of the 209 participants, 188 had drug resistance results available
at VF (Table 2). Only 1 participant selected a new major PI-as-
sociated mutation since ART initiation (0.5%), although anoth-
er 4 participants had such mutations at baseline; 15 (9%)
selected new NRTI-associated mutations, with 23 having
these at baseline; and 7 (4%) had NNRTI-associated mutations,
all present at baseline. Among the 61 participants who were ex-
cluded, resistance was also infrequent at VF: none had major PI-
associated resistance and 7% and 4% had NRTI and NNRTI re-
sistance, respectively. Compared with the 209 participants includ-
ed, the participants excluded did, however, have significantly
higher median pretreatment CD4 counts (277 vs 165 cells/µL;
P < .001) and lower median pretreatment HIV-1 RNA (4.66 vs
4.84 log10 copies/mL; P = .006).
ART Regimen After First-line Virologic Failure
Participants who did not change ART regimen through 24 weeks
after first-line VF confirmation were defined as remaining on
their first-line regimen, whereas participants who changed regi-
mens within 24 weeks were classified by the type of their first reg-
imen change. Among the 209 participants, 137 (66%) remained
on their first-line regimen, 28 (13%) changed to an NNRTI-based
regimen (with or without NRTI change), 14 (7%) changed to
a different PI/r (with or without NRTI change), 25 (12%)
only changed 1 or both of their NRTIs, and 5 (2%) changed
to a nonstandard second-line regimen (2 changed to a PI/
r + NNRTI + NRTI regimen, and 3 changed to an unboosted
PI + NRTI regimen) (Table 3). The proportion of participants
remaining on their first-line regimen differed significantly
among the 3 studies: 51% for A5142, 69% for A5202, and
83% for A5208 (P = .003).
Participants remaining on their first-line regimen had a higher
CD4 count at VF than those who changed (median, 275 vs 213
cells/µL; P = .005). Among A5142 and A5202 participants with
real-time resistance test results available at VF, those remaining
on their first-line regimen were less likely to have NRTI resistance
mutations (11% vs 30%; P = .003). There were no significant dif-
ferences for other factors evaluated.
Virologic Suppression After First-line Virologic Failure
At 24 weeks after confirmation of first-line VF, 136 of 204 par-
ticipants (67%) had HIV-1 RNA <400 copies/mL (excluding
the 5 on nonstandard regimens; Table 4): 88 (64%) of those
who remained on their first-line regimen and 48 (72%) of
those who changed (odds ratio [OR], 0.74 [95% confidence in-
terval {CI}, .48–1.16]; P = .19; if adjusted for CD4 count and
presence of NRTI resistance mutations at VF: OR, 0.75 [95%
CI, .36–1.58]; P = .45). Among the 146 participants without
NRTI-, NNRTI-, or major PI-associated resistance mutations
detected, the proportion with virologic suppression was 62%
for those who remained on their first-line ART and 61% for
those who changed (OR, 0.97 [95% CI, .61–1.54]; P = .89).
Among participants from A5142 and A5202 (which used a
more sensitive HIV-1 RNA assay), 62 participants (57%) who
Table 3. Antiretroviral Therapy Regimen Within 24 Weeks After





















6 (9%) 8 (7%) 0 (0%) 14 (7%)
Changed NRTI(s)
only





4 (6%) 1 (1%) 0 (0%) 5 (2%)
Abbreviations: ART, antiretroviral therapy; NNRTI, nonnucleoside reverse
transcriptase inhibitor; NRTI, nucleoside reverse-transcriptase inhibitor; PI,
protease inhibitor.
a The 5 participants who changed to a nonstandard second-line regimen
included 2 who changed to a ritonavir-boosted PI + NNRTI-based regimen
and 3 who changed to a PI regimen without ritonavir boosting.
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remained on their first-line ART and 40 participants (69%) who
changed had HIV-1 RNA <200 copies/mL at 24 weeks after
first-line VF confirmation (P = .34) (Table 4).
Among the 137 participants remaining on their first-line reg-
imen, the following factors were significantly associated with
higher odds of virologic suppression at week 24 after first-line
VF in univariate analysis: greater increase in CD4 count and lon-
ger time fromART initiation to VF, HIV-1 RNA <400 copies/mL
at any time prior to VF, and HIV-1 RNA <10 000 copies/mL at
VF confirmation. Two variables remained significantly associated
in multivariate analysis: HIV-1 RNA <400 copies/mL at any time
prior to VF (OR, 3.39 vs ≥400 copies/mL; P = .011), and HIV-1
RNA <10 000 copies/mL at VF (OR, 3.35 vs ≥10 000 copies/mL;
P = .007) (Table 5). No significant interaction was detected
between these 2 variables.
Among the 137 participants remaining on their first-line reg-
imen, 126 (92%) had self-reported adherence data available
after VF: 84 (67%) reported 100% adherence during the
4 days prior to evaluation, 35 (28%) reported <100% adherence,
and 7 (6%) were not on ART at the evaluation. The virologic sup-
pression rate was 75% for participants who reported 100% adher-
ence, compared with 54% for participants reporting <100%
adherence (OR, 0.38; P = .044), and 15% for participants not on
ART (OR, 0.06; P = .016) (Table 6). Similar results were found
when adjusted for whether or not a participant achieved HIV-1
RNA <400 copies/mL prior to VF and for HIV-1 RNA at VF.
For the 67 participants who changed ART within 24 weeks
after first-line VF, the median time from VF confirmation to
regimen change was 10 weeks. Forty-three (64%) had HIV-1
RNA <400 copies/mL at 24 weeks after regimen change, includ-
ing 20 (71%) of 28 participants who switched to a NNRTI-
containing regimen, 6 (44%) of 14 who changed to a different
PI/r, and 18 (72%) of 25 who only changed 1 or more NRTIs
(P = .39). Achieving HIV-1 RNA <400 copies/mL prior to VF
was the only significant factor associated with higher suppres-
sion rate at 24 weeks after regimen change (OR, 6.50 [95%
CI, 1.91–22.11]; P = .003).
Results consistent with those reported above were ob-
served in sensitivity analyses, with the exception that, in
the analysis restricted to A5142 and A5202 participants in
which virologic suppression was defined as HIV-1 RNA
<200 copies/mL, virologic suppression rates at 24 weeks
after regimen change differed significantly by type of change
(67% of the 15 participants who changed to a NNRTI-based
regimen, 33% of the 6 participants who changed to another
PI/r, and 57% of the 7 participants who only changed NRTIs;
P = .028).
DISCUSSION
This study provides important information that adds to the cur-
rent knowledge regarding management of ART after VF on
Table 4. Virologic and Immunologic Outcome at 24 Weeks After First-line Virologic Failure Confirmation
Change ART Within 24 wk Post–Virologic Failure A5142 A5202 A5208 Overall P Valuea
HIV-1 RNA <400 copies/mL
No change in ART 20/34 (59%) 45/74 (61%) 23/29 (79%) 88/137 (64%) .19
ART changedb 21/29 (72%) 22/32 (69%) 5/6 (83%) 48/67 (72%)
Total 41/63 (65%) 67/106 (63%) 28/35 (80%) 136/204 (67%)
HIV-1 RNA <200 copies/mL
No change in ART 20/34 (59%) 42/74 (57%) Not availablec 62/108 (57%) .34
ART changedb 20/29 (69%) 20/32 (63%) Not available 40/61 (66%)
Total 40/63 (63%) 62/106 (58%) Not available 102/169 (60%)
CD4+ cell count, cells/µL
No change in ART 304 (221–461) 313 (205–520) 268 (205–437) 304 (205–469) .02
ART changedb 308 (218–412) 253 (160–341) 207 (177–200) 273 (194–351)
Total 304 (221–445) 286 (194–463) 256 (197–432) 287 (198–439)
CD4+ cell count change, cells/µL, since first-line virologic failure confirmation
No change in ART 24 (−33–102) 19 (−93–96) 73 (6–149) 34 (−40–100) .34
ART changedb 30 (−6–119) 65 (−18–88) −3 (26–51) 44 (−19–87)
Total 30 (−25–113) 43 (−33–93) 51 (−23–97) 38 (−27–96)
Data are presented as No. (%) or median (first quartile - third quartile).
Abbreviations: ART, antiretroviral therapy; HIV-1, human immunodeficiency virus type 1.
a The P value was from the test comparing outcomes in participants who remained on the first-line regimen and those who changed regimen after first-line failure.
b Five participants who changed to a nonstandard care second-line regimen (3 changed to a unboosted protease inhibitor [PI] regimen and 2 changed to a ritonavir-
boosted PI plus nonnucleoside reverse transcriptase inhibitor regimen) after first-line virologic failure were excluded from outcome evaluation.
c Not available for A5208 participants because the lower limit of quantification of the assay used in A5208 was 400 copies/mL.
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first-line PI/r plus 2 NRTIs. Of note, our study suggests that a
large proportion of patients failing these regimens can subse-
quently achieve virologic suppression without changing their
ART regimen, particularly if no resistance is detected, if
virologic suppression was ever achieved prior to VF, and if
self-reported treatment adherence is good.
Our study included participants in randomized trials who
experienced VF on PI/r-based regimens. The proportion of
Table 5. Variables Associated With HIV-1 RNA <400 Copies/mL at Week 24 After Confirmation of First-line Virologic Failure for
Participants Remaining on First-line Antiretroviral Therapy
Univariate Modela Multivariable Modelb
Variable
Odds Ratio
(95% CI) P Value
Odds Ratio
(95% CI) P Value
Sex Female vs Male 0.89 (.38–2.05) .78
NRTI in initial regimen Lamivudine + otherc vs
tenofovir + emtricitabine
1.02 (.40–2.58) .97
HIV-1 RNA at ART initiation Per 1 log10 copies/mL higher 1.27 (.78–2.09) .34
CD4 count at ART initiation Per 100 cells/µL higher 1.02 (.82–1.27) .89
Age at virologic failure Per 10 ys increase 1.00 (.97–1.04) .83
CD4 change from baseline to virologic
failure confirmation
Per 100 cells/µL increase 1.41 (1.06–1.87) .02
Self-reported adherence at virologic
failure
<100% vs 100% 1.53 (.59–3.96) .39
Not on ARV vs 100% 0.95 (.36–2.47) .91
CD4 count at virologic failure
confirmation
Per 100 cells/µL higher 0.98 (.79–1.21) .84
Achieved HIV-1 RNA <400 copies/mL at
any time prior to initial failure
Yes vs No 4.57 (1.83–11.38) .001 3.39 (1.32–8.73) .011
HIV-1 RNA at virologic failure
confirmation
<10 000 vs ≥10 000 copies/mL 4.21 (1.83–9.67) <.001 3.35 (1.40–8.01) .007
Any NRTI resistanced at virologic failure Yes vs No 4.05 (.88–18.73) .07
Any minor PI resistanced at virologic
failure
Yes vs No 0.49 (.09–2.57) .40
Time from ART initiation to virologic
failure
Per 10 wks increase 1.13 (1.02–1.26) .02
Abbreviations: ART, antiretroviral therapy; ARV, antiretroviral; CI, confidence interval; HIV-1, human immunodeficiency virus type 1; NRTI, nucleoside reverse
transcriptase inhibitor; PI, protease inhibitor.
a Both univariate model and multivariable model was stratified by study.
b Multivariable model was selected by stepwise procedure with entry and inclusion, P < .05.
c
“Other” refers to one of abacavir, tenofovir, zidovudine, or stavudine.
d Resistance mutations were defined as those listed by the International Antiviral Society (IAS)–USA for A5142 (2006 version) [12] and A5208 (2008 version) [13]; for
A5202, they were defined as those listed by the IAS-USA 2008 version [13], as well as T69D, L74I, and G190C/E/Q/T/V for major reverse transcriptase–associated
mutations, and L24I, F53L, I54V/A/T/S, G73C/S/T/A, and N88D for major protease-associated mutations.
Table 6. Self-Reported Adherence of Study Treatment After First-line Virologic Failure and Association With Virologic Suppression (HIV-
1 RNA <400 Copies/mL) at Week 24 After First-line Virologic Failure for Participants Remaining on the First-line Regimen
Adherence Within the Past 4 d No. Suppression Rate
Univariate Analysisa Adjusted Analysisb
Odds Ratio (95% CI) P Value Odds Ratio (95% CI) P Value
100% 84 63 (75%) Reference level Reference level
<100% 35 19 (54%) 0.43 (.19–.99) .046 0.38 (.15–.97) .044
Not on ART 7 1 (14%) 0.07 (.01–.58) .014 0.06 (.01–.59) .016
Abbreviations: ACTG, AIDS Clinical Trials Group; ART, antiretroviral therapy; CI, confidence interval; HIV-1, human immunodeficiency virus type 1; OR, odds ratio.
a Both univariate and adjusted analysis was stratified by ACTG study.
b Analysis was adjusted by whether achieving HIV-1 RNA <400 copies/mL at any time prior to initial failure and whether HIV-1 RNA at first-line virologic failure
<10 000 copies/mL. In this model, achieving HIV-1 RNA <400 copies/mL at any time prior to initial failure remained significant (odds ratio [OR], 5.01 [95% CI,
1.77–14.24]; P = .002), but not HIV-1 RNA <10 000 copies/mL at the time of virologic failure (OR, 2.41 [95% CI, .81–5.98]; P = .12).
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participants with treatment-emergent mutations at VF was low
—0.5% for major PI-associated and 9% for NRTI-associated
mutations. The most common therapeutic strategy within 24
weeks after VF (66%) was to continue the same first-line regi-
men; 64% of participants doing this achieved HIV-1 RNA <400
copies/mL after 24 weeks. This did not differ significantly from
the rate (72%) among those who changed regimen. Because the
proportion of participants with resistance-associated mutations
was higher among those who changed regimen vs those who did
not, we also evaluated virologic suppression rates among the
subgroup of participants with no such mutations detected at
first-line VF; subsequent suppression rates were almost identical
in those who remained on their initial ART regimen vs those
who changed (62% vs 61%).
The rarity of major PI-associated resistance mutations fol-
lowing VF on PI/r regimens in this study is consistent with find-
ings in other studies [7–10], resulting from several possible
mechanisms: one is a high genetic barrier to resistance and
the higher drug concentration achieved with ritonavir boosting
[7]; another is that PIs have inhibitory effects in multiple steps
in the viral life cycle and act like multiple drugs in one [14]; and
a third one is the limited time period during which resistance
can be selected due to the short pharmacokinetic half-lives of
PI/r regimens allowing rebound of susceptible virus [15]. This
raises the possibility, as seen in our study, for subsequent viro-
logic suppression with continued use of the same regimen.
Other studies have also shown that delay in treatment switch
after failing first-line PI/r does not have substantial impact on
subsequent outcome [16, 17]. In the absence of measurable
drug resistance, continuing a first-line PI/r regimen might
therefore be a reasonable approach, especially for those with
lower HIV-1 RNA at VF and successful suppression of HIV-1
RNA prior to VF, as suggested by our multivariate analysis
(Table 5). However, these findings should not undermine the
importance of resistance testing at the time of VF on a first-
line PI/r-based regimen; although the rate of PI resistance was
low in our study, there was a higher rate of NRTI resistance. Our
study was not able to examine the impact that NRTI resistance
had on outcome because these participants were more likely to
have regimen changes following VF, and the number with NRTI
resistance who remained on the same PI/r-based regimen was
small.
For participants who changed ART regimens after first-line
VF, no difference in rates of virologic suppression to <400 cop-
ies/mL after regimen change was detected among different reg-
imens. However, our study had limited sample size for
participants who changed regimens after failing first-line PI/r,
restricting the power to detect possible differences among regi-
mens. A sensitivity analysis did, however, suggest that changing
to a different PI/r-containing regimen gave a lower rate of sup-
pression to <200 copies/mL than other regimen changes. The
latter is similar to the findings in a German cohort, which sug-
gested that switching to a NNRTI-based regimen had im-
proved durability compared with switching to a different PI
after VF [18]. However, the newer PI darunavir was not
used in these studies, and its use might give better outcomes.
As for participants who did not change regimen, achieving an
HIV-1 RNA <400 copies/mL prior to initial VF was a signifi-
cant predictor of subsequent suppression among those who
changed regimens. Such prior suppression may be a marker
of adequate adherence that is realizable again following VF
whether or not a regimen is changed. This is consistent with
other studies that have shown that improved adherence after
first-line VF is important for the subsequent virologic sup-
pression with or without regimen change [17, 19, 20], and em-
phasizes the need for ongoing efforts to promote good
adherence following VF.
Our study has some limitations, and the findings need to be
interpreted with caution. First, our study was observational and
involved follow-up of participants in clinical trials. Hence, ART
management after first-line VF was not randomized, and treat-
ment options as well as the definition of VF and assays used var-
ied among the 3 studies and between study sites. Identification
of VF and subsequent treatment management may have been
quicker in these trials than would occur in practice. Also, data
were not collected to allow an evaluation of the extent to which
a physician’s assessment of a patient’s adherence to treatment
and low-grade PI/r-related toxicity might have determined the
approach to treatment management following VF. Second, de-
spite the fact that we combined data from >200 participants
from 3 large clinical trials who experienced first-line VF, this
sample size likely provides inadequate power to identify some
factors that might be associated with clinically relevant differ-
ences in outcome. Third, 23% of participants who experienced
VF on a PI/r-based regimen were excluded because of limited or
no follow-up after VF. The excluded participants had higher
CD4 count and lower HIV-1 RNA prior to starting ART than
those included but, like those included, had limited resistance at
first-line VF. Although we cannot fully assess the impact of
these exclusions on our results, among the 21 excluded who
had some follow-up, a similar percentage (62%) achieved
HIV-1 RNA <400 copies/mL at their last available measure-
ment after initial VF as among included participants at 24
weeks after VF (67%).
CONCLUSIONS
Our findings suggest that if no or limited drug resistance is de-
tected at VF on a first-line PI/r-containing regimen, remaining on
the same regimen after VF coupled with strategies to improve ad-
herence could be a reasonable and effective approach to achieving
virologic suppression. Further evaluation of approaches to
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treatment management following VF on a first-line PI/r-
containing regimen is warranted.
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